DBV Applied sciences: research recruitment accomplished
DBV Applied sciences reviews that it accomplished topic enrolment in August, a month forward of schedule, for the Section III VITESSE research evaluating its Viaskin Peanut patch in peanut-allergic youngsters aged 4 to seven.
This 12-month research is evaluating the efficacy and security of Viaskin Peanut in over 600 topics (randomized 2:1), representing people at 86 websites in america, Canada, Europe, the UK and Australia.
The biopharmaceutical firm factors out that VITESSE is presently the biggest therapeutic intervention research in peanut allergy. Preliminary outcomes are anticipated within the fourth quarter of 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.